Abstracts tagged "outcomes and psoriatic arthritis"

Abstract Number: 2138 • 2018 ACR/ARHP Annual Meeting
Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
Brian Ung¹, Dionne Hines², Sandhya Mehta¹, Corey Pelletier¹, Xin Wang² and Rolin Wade², ¹Celgene Corporation, Summit, NJ, ²IQVIA, Durham, NC
Background/Purpose: Methotrexate (MTX) is commonly used to treat psoriatic arthritis (PsA), yet data supporting its effectiveness in PsA are limited. This analysis describes real-world dosing,…
Abstract Number: 694 • 2016 ACR/ARHP Annual Meeting
Diagnostic Delay Leads to Worse Response to Treatment
Marijn Vis¹, Kim Wervers², Ilja Tchetverikov³, Mark R. Kok⁴, Lindy-Anne Korswagen⁵, Andreas H. Gerards⁶, Hans van Groenendaal⁷, Jozien Veris⁸, Wiebo L. van der Graaff⁹, Cathelijne W. Y. Appels¹⁰, Johanna M.W. Hazes¹¹ and Jolanda J. Luime¹, ¹Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁷Rheumatology, ReumaZorg ZuidWest nederland, Roosendaal, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁹Rheumatology, Rivas hospital, Gorinchem, Netherlands, ¹⁰Rheumatology, Amphia Hospital, Breda, Netherlands, ¹¹Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands
Is there a clinical patient profile for PsA Patients with a diagnostic delay? Background/Purpose: Psoriatic arthritis (PsA) is a progressive inflammatory musculoskeletal disease. Several recent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].